{"id":"tapentadol-er-cg5503","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL1201776","moleculeType":"Small molecule","molecularWeight":"221.34"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tapentadol ER works by activating the mu-opioid receptor, which is responsible for pain relief, and inhibiting the reuptake of norepinephrine, a neurotransmitter that also contributes to pain relief. This dual mechanism of action provides effective pain relief with a lower risk of opioid-related side effects.","oneSentence":"Tapentadol ER is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:25.194Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain"},{"name":"Acute pain"}]},"trialDetails":[{"nctId":"NCT00505414","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine","status":"TERMINATED","sponsor":"Grünenthal GmbH","startDate":"2007-06","conditions":"Pain, Neoplasm, Cancer","enrollment":136},{"nctId":"NCT00486811","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2007-06","conditions":"Pain, Knee Osteoarthritis","enrollment":990},{"nctId":"NCT01631513","phase":"PHASE4","title":"An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)","status":"WITHDRAWN","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2012-08","conditions":"Pain, Chronic Back Pain, Chronic Low Back Pain","enrollment":""},{"nctId":"NCT01165281","phase":"PHASE3","title":"A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-08","conditions":"Pain","enrollment":343},{"nctId":"NCT02920762","phase":"","title":"Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers","status":"UNKNOWN","sponsor":"ER/LA Opioid REMS Program Companies (RPC)","startDate":"","conditions":"Opioid Related Disorders, Opiate Addiction, Narcotic Abuse","enrollment":5575834},{"nctId":"NCT00594516","phase":"PHASE3","title":"Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-12","conditions":"Low Back Pain","enrollment":117},{"nctId":"NCT00487435","phase":"PHASE3","title":"An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-06","conditions":"Pain, Osteoarthritis, Low Back Pain","enrollment":1166},{"nctId":"NCT00361504","phase":"PHASE3","title":"A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain","enrollment":1123},{"nctId":"NCT01063868","phase":"PHASE3","title":"A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-01","conditions":"Diabetic Neuropathy, Painful, Diabetic Polyneuropathy","enrollment":47},{"nctId":"NCT01309425","phase":"PHASE1","title":"A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-02","conditions":"Healthy Volunteer","enrollment":52},{"nctId":"NCT01124617","phase":"PHASE2","title":"A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2010-06","conditions":"Pain, Diabetic Neuropathies, Neuralgia","enrollment":91},{"nctId":"NCT02019485","phase":"PHASE1","title":"A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-07","conditions":"Healthy","enrollment":64},{"nctId":"NCT01981278","phase":"PHASE1","title":"A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-07","conditions":"Healthy","enrollment":63},{"nctId":"NCT01900587","phase":"PHASE1","title":"A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-07","conditions":"Healthy","enrollment":64},{"nctId":"NCT01041859","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2009-12","conditions":"Diabetic Peripheral Neuropathy","enrollment":460},{"nctId":"NCT00455520","phase":"PHASE3","title":"A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-04","conditions":"Diabetic Neuropathy","enrollment":395},{"nctId":"NCT01124604","phase":"PHASE2","title":"An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2010-04","conditions":"Pain, Low Back Pain, Back Pain","enrollment":91},{"nctId":"NCT01309386","phase":"PHASE3","title":"A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2010-08","conditions":"Neoplasms","enrollment":100},{"nctId":"NCT00449176","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-02","conditions":"Low Back Pain","enrollment":981},{"nctId":"NCT00421928","phase":"PHASE3","title":"Tapentadol (CG5503)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-01","conditions":"Osteoarthritis, Knee, Pain","enrollment":1030},{"nctId":"NCT01273506","phase":"PHASE1","title":"A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-12","conditions":"Healthy Volunteer","enrollment":30},{"nctId":"NCT01273532","phase":"PHASE1","title":"A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-12","conditions":"Healthy Volunteer","enrollment":30},{"nctId":"NCT00784277","phase":"PHASE3","title":"A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-10","conditions":"Joint Diseases, Arthritis, Osteoarthritis","enrollment":597}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CG5503"],"phase":"phase_3","status":"active","brandName":"Tapentadol ER (CG5503)","genericName":"Tapentadol ER (CG5503)","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tapentadol ER is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor. Used for Chronic pain, Acute pain.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}